Fig. S1.

Trial consort diagram. The current study is nested within the ImmunoSPIN trial, with a total of 4,004 individuals in two participating villages who were allocated to placebo and albendazole treatment. For the immunological studies, a random selection was made. Cytokines were assessed for 1,059 subjects, of which 572 were in the placebo and 487 in the albendazole arm. After 9 mo, 504 and 428 and, after 21 mo, 434 and 364 individuals were analyzed in the placebo and albendazole group, respectively. Availability of CBCs and parasitological data are indicated at the different time points for both groups.